• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:俞榕榕,邓逸苹,刘滢,林苇婷,秦晓静,杨成梓,贺龙刚,陈剑钰.厚朴酚与和厚朴酚对慢性疾病现代药理研究进展[J].药学研究,2025,44(9):893-899[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2397次   下载 740次 本文二维码信息
码上扫一扫!
厚朴酚与和厚朴酚对慢性疾病现代药理研究进展
俞榕榕,邓逸苹,刘滢,林苇婷,秦晓静,杨成梓,贺龙刚,陈剑钰
字体:加大+|默认|缩小-
(福建中医药大学药学院,福建 福州 350122)
摘要:
厚朴临床常用于治疗胃肠和肺部疾病,厚朴酚与和厚朴酚是厚朴的主要活性成分,近年来大量研究表明二者具有抗炎、抗氧化和抗肿瘤等多种药理作用,而炎症为多种慢性疾病的共病基础,表明其具有治疗多种疾病的潜力,其临床应用仍有提升空间。本文综述了近5年国内外厚朴及其主要活性成分厚朴酚与和厚朴酚治疗慢性疾病的研究进展,发现它们可以从多种途径分别调控免疫紊乱、炎症和氧化应激,从而实现抗炎和抗关节炎;此外,厚朴酚与和厚朴酚还可通过激动糖尿病热门靶点—过氧化物酶体增殖物激活受体γ(PPARγ)进而降低血糖,改善糖尿病并发症,认知障碍及脂代谢紊乱,即便在胰岛素抵抗型小鼠模型中它们仍具有明显降糖作用。本文将深入探讨厚朴酚与和厚朴酚在治疗多种慢性疾病的作用及优势,为拓展厚朴及其活性成分(厚朴酚与和厚朴酚)应用提供依据。
关键词:  厚朴酚  和厚朴酚  厚朴  慢性疾病
DOI:10.13506/j.cnki.jpr.2025.09.011
基金项目:国家自然科学基金项目(No.82474150)
出版日期:2025-09-25
Research progress on modern pharmacology of magnololand honokiol in chronic disease
YU Rongrong,DENG Yiping,LIU Ying,LIN Weiting,QIN Xiaojing,YANG Chengzi,HE Longgang,CHEN Jianyu
(School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China)
Abstract:
Magnolia officinalis is often used clinically to treat gastrointestinal and lung diseases. Magnolol and honokiol are the main active ingredients of Magnolia officinalis. In recent years, a large number of studies have shown that they have various pharmacological effects such as anti-inflammatory, antioxidant and anti-tumor.Inflammation is the comorbidity basis of multiple chronic diseases, indicating that it has the potential to treat multiple diseases, and its clinical application still has room for improvement. This article reviews the research progress of magnolia officinalis and its main active ingredients magnolol and honokiol in the treatment of chronic diseases at home and abroad in the past five years. It is found that they can regulate immune disorders, inflammation and oxidative stress from multiple cellular pathways, thereby achieving anti-inflammation and anti-arthritis; In addition,magnolol and honokiol can also lowers blood sugar by stimulating the popular target of diabetes,peroxisome proliferator activated receptor gamma (PPARγ), and improves diabetic complications, cognitive impairment and lipid metabolism disorders. Even in insulin-resistant mouse models, they still have significant blood sugar lowering effect. This article will discuss in detail the role and advantages of magnolol and honokiol in the treatment of various chronic diseases, and provide basis for expanding the application of Magnolia officinalis and its active ingredients (magnolol and honokiol).
Key words:  Magnolol  Honokiol  Magnoliae Officinalis  Chronic diseases
今日访问量:2460    总访问量:55338887
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司